ClinicalTrials.gg
RecruitingNCT07394296MIDRELAYUpdated Feb 10, 2026

Study of the Prevalence of Midline Replacements and the Reasons for These Replacements

An observational study in Veinous Access, Midline and Veinous Capital, sponsored by Centre Hospitalier de Valenciennes. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-10.

Sponsored by Centre Hospitalier de Valenciennes · Observational

How we know

From the registry’s dates

  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
984
Ages
18 Years and older
Sex
All
01

Study summary

Venous access management plays a key role in patient care and preserving their venous capital. The so-called "conventional" peripheral venous catheter is the most common venous access device, but it is associated with a high rate of complications, particularly in cases of prolonged use or poor venous capital. Recommendations, such as those from MAGIC or SF2H, advocate their use when the intended duration of use is 5 days or less. For longer periods or in cases of difficult access, so-called "central" devices such as PICC lines or central venous catheters are used, although they present specific risks such as CLASBI or deep vein thrombosis.

In intermediate situations, the midline, a peripheral venous access device, is a relevant alternative, particularly for non-venotoxic intravenous treatments lasting more than 5 days. Although it is theoretically associated with fewer infections and complications than the PICCline, its complication rate and actual duration of use vary widely in the literature.

The MAGIC recommendations suggest using them for periods of 14 days or less. The widespread use of midlines in healthcare facilities, and in particular the creation of vascular access units, has given rise to issues shared between centers, notably the replacement rate of these devices. The study therefore aims to determine the replacement and early removal rates for midlines, the circumstances in which they are replaced, and toassess the relevance of the 28-day limit in the choice of device, in order to improve practices and optimize the practitioner's initial decision.

02

Conditions studied

  • Veinous Access
  • Midline
  • Veinous Capital

Keywords

  • midline
  • midline placement
  • midline indication
  • patient care
03

In context

Lead sponsor

Centre Hospitalier de Valenciennes is the lead sponsor of 15 studies on the registry; 9 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients included in the study are those whose midline indication has been validated by the vascular access unit according to the hospital's organization. The expected duration of midline use should be 28 days or less.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over 18 years of age.
  • Patients who have given their consent to participate in the study.
  • Patients treated in a hospital unit authorized to insert midlines, or who have a midline inserted by a professional trained in this procedure, in accordance with the local organization of each center.
  • First insertion for the treatment of a given event with an expected treatment duration of 28 days or less.
  • Patients treated with a midline catheter at least 14 cm in length.

Exclusion criteria

Exclusion Criteria:

  • No coverage by the social security system
  • Failure to insert the midline
  • Patient under guardianship or conservatorship
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
984 participants (estimated)
Target follow-up
33 Days
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Evaluate the midline replacement rate regardless of the indication, in the various requesting centers

    The primary endpoint is the cumulative incidence rate of midline replacement over a censored period of 28 days. This period begins on the day of inclusion with the first midline placement, regardless of the indication. Competing events are removal without replacement, regardless of the cause (death, removal at the end of treatment, early removal before the end of treatment without replacement).

    Time frame: within 28 days after the initial placement of the midline

Secondary outcomes

  1. Secondary objective 1: To evaluate the early removal rate among patients living with midlines within 28 days of placement.

    Cumulative incidence rate of early removal of midlines placed on the day of inclusion over a censored period of 28 days. Competing events are death and removal due to end of treatment

    Time frame: over a censored period of 28 days

  2. Secondary objective 2: Describe the reasons for early removal of midlines.

    Midline removal rate for each of the following reasons: * Extravasation/diffusion of the product * Suspected midline infection * Confirmed midline infection * Accidental removal * Catheter-induced deep vein thrombosis * Catheter occlusion * Inability to perform sampling * Conversion to PICCline * Duration exceeded

    Time frame: Withdrawals are analyzed from the day of inclusion and over a censored period of 28 days

  3. Secondary objective 3: Describe the lifespan of midlines

    Midline lifespan. The event is the removal of the midline regardless of the cause: removal at the end of treatment, removal due to death, early removal (with or without reinsertion).

    Time frame: This duration includes the number of days between the day of inclusion and the day of device removal over a censored period of 28 days.

  4. Secondary objective 4: Describe the replacement rate of midlines among midlines still in place at different time

    Cumulative incidence rate of midline recurrence with a benchmark at D7, D14, then D21, censored at D28

    Time frame: Days 7, 14, 21 and 28

  5. Secondary objective 5: Compare the midline replacement rate between the initial indication of antibiotic therapy and the initial indication of insufficient venous capacity

    Cumulative incidence rate of midline removal for the initial indication of antibiotic therapy and midline removal rate for the initial indication of insufficient venous access. The midlines analyzed are those placed on the day of inclusion. Concurrent events are removal without replacement regardless of the cause (death, removal at the end of treatment, early removal before the end of treatment without replacement).

    Time frame: Replacements taken into account occur over a censored period of 28 days beginning on the day of inclusion

07

Study locations

1 of 1 sites recruiting
  • Centre Hospitalier de Valenciennes
    Valenciennes, 59300, France
    Recruiting
    • Jean-Baptiste VARANGUIEN DE VILLEPIN, MD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2025 (actual). Primary completion is estimated for Jan 2027, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2026
First posted
Feb 6, 2026
StartActual
Dec 2, 2025
Primary completionEst.
Jan 5, 2027
CompletionEst.
Jan 5, 2027
Last update
Feb 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07394296
Lead sponsor
Centre Hospitalier de Valenciennes
Responsible party
Sponsor
First posted
Feb 6, 2026
Start date
Dec 2, 2025
Primary completion
Jan 5, 2027 (estimated)
Completion
Jan 5, 2027 (estimated)
Last update
Feb 10, 2026

Study contacts

Fanny DEFRANCQ, MD
Contact
defrancq-f@ch-valenciennes.fr
0327149153

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion